Monash University and Seaport Therapeutics have developed a new approach to delivering drug molecules that piggybacks onto natural fat absorption pathways to allow oral delivery of some drugs previously requiring injection. ...
Mar 25, 2026
0
8
There's a reason that the term "mom brain" exists. In recent years, research has shown that the forgetfulness and general fogginess that mothers can experience after giving birth, both immediately and in the long term, is ...
Mar 3, 2026
0
16
Depression, characterized by persistent sadness, hopelessness and a lack of interest in previously enjoyed activities, is one of the most common mental health disorders. Recent estimates by the World Health Organization (WHO) ...
A number of videos have surfaced recently on social media with women claiming that common medications used to treat allergies and heartburn have helped them manage symptoms of premenstrual dysphoric disorder (PMDD). But is ...
Apr 10, 2025
0
24
A new study led by researchers at UF Health has uncovered why males and females may experience stress differently, providing crucial insights into how the brain's molecular mechanisms adapt to acute challenges.
Feb 13, 2025
1
45
Researchers at Stony Brook University used genetic manipulation in a laboratory brain model to demonstrate that neurosteroids, signals involved in mood regulation and stress, can reduce the sensitivity and preference for ...
Feb 10, 2025
0
40
It turns out flatulence can serve a purpose beyond being uncomfortable or funny: Gas released by some gut bacteria stimulates other gut bacteria to produce a hormone involved in pregnancy and in an FDA-approved treatment ...
May 27, 2024
0
51
Research from the University of Virginia School of Medicine could pave the way for new treatments to manage migraines and chronic pain in women, improving their quality of life. The work is published in The Journal of Pain.
Feb 21, 2024
0
36
The first postpartum depression pill approved for use in the United States is now available to women who need it, the drug's makers announced Thursday.
Dec 15, 2023
0
40
On Aug. 4, 2023, the United States Food and Drug Administration (FDA) approved zuranolone (Zurzuvae) as the first oral neurosteroid treatment for postpartum depression (PPD) in women.
Oct 20, 2023
0
71
